PDCD1 and colorectal carcinoma: In practice, pembrolizumab (anti-PD1) has been approved for dMMR/MSI-H refractory or metastatic solid tumors, and nivolumab (anti-PD1) for dMMR/MSI-H CRC [241,242,243].